UNICANCER Breast Group

Unicancer Breast Group (UCBG) is a leading French academic research organization dedicated to advancing the treatment of breast cancer through large-scale clinical trials and translational research. Operating as a specialized group within the Unicancer federation, UCBG coordinates a network of Comprehensive Cancer Centers to design and execute multicenter studies ranging from Phase I to Phase III. The group is internationally recognized for its focus on precision medicine and genomic profiling, exemplified by landmark trials such as SAFIR02 and PADA-1. By collaborating with both global pharmaceutical partners and international cooperative groups like the Breast International Group (BIG), UCBG plays a pivotal role in establishing new standards of care. Its research portfolio covers the entire spectrum of the disease, including early-stage, metastatic, and triple-negative breast cancers.